X

Sharon Smith

Ten ASX medical imaging stocks that make a pretty picture

Advances in technology and an increasing demand from doctors to assess diseases close-up is expected to push the global market…

Outlook is bright for Aussie 3D printing stocks – if they can win patents

The outlook for ASX-listed 3D printer makers is strong -- as long as they can win patents, a top expert…

With no HIV cure in sight, Biotron focuses on China Hep C patients

You could be forgiven for thinking that a cure for HIV had been found when, on World AIDS Day, scientists…

Promising results as Paradigm repurposes drug for osteoarthritis

As the Australian pharmaceutical sector plans a crackdown on opioid oversupply to consumers, Paradigm Biopharmaceuticals (ASX:PAR) has released its progress…

Biotechs face stronger regulation of stem cell treatment

Stem cell therapy is an exciting area of medicine. There’s something futuristic about using your own cells to heal yourself.…

Opthea eyes new treatments for macular degeneration

Aussie biotech Opthea is hoping to find a treatment for two eye diseases that have a wide impact on the population.…

Why doctors use WhatsApp to share patient data

Doctors are using personal messaging apps like WhatsApp to share patient information in some Australian hospitals because communications technology is…

Can Rhinomed help the world get a good night’s sleep?

Jenny Chapman snores like a chainsaw, literally. At 111 decibels, she has the title of Britain’s Loudest Snorer, one decibel…

Dr Graham Kelly’s Noxopharm expects NOX66 cancer drug trial results by Christmas

Not many medical researchers have more incentive than Dr Graham Kelly. While working to develop drugs that make cancer treatments…